Novel nutritional treatment for manic and psychotic disorders: A review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide

Psychopharmacology

Volumn 228, Issue 3, 2013, Pages 347-358

  Badawy, Abdulla ^a  

^a CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Acute amino acid depletion and loading tests; Bipolar disorders; Branched chain amino acids; Dopamine synthesis; Glycomacropeptide; Nutritional therapy; Phenylalanine; Psychotic disorders; Schizophrenia; Tryptophan; Tyrosine; Whey protein

Indexed keywords

ALPHA LACTALBUMIN; ARIPIPRAZOLE; BRANCHED CHAIN AMINO ACID; GLYCOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; TRYPTOPHAN; TYROSINE;

AMINO ACID ANALYSIS; AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; BIPOLAR DISORDER; DECARBOXYLATION; DIETARY INTAKE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; ENZYME SYNTHESIS; HORMONE INHIBITION; HUMAN; LOADING TEST; MANIA; MINERALIZATION; NEUROTRANSMISSION; NONHUMAN; OXIDATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROLACTIN BLOOD LEVEL; PROTEIN SYNTHESIS; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BIPOLAR DISORDER; BRAIN; CASEINS; HUMANS; NEUROPSYCHOLOGICAL TESTS; NUTRITIONAL REQUIREMENTS; PEPTIDE FRAGMENTS; PSYCHOTIC DISORDERS; TRYPTOPHAN; TYROSINE;

EID: 84880292331     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3191-9     Document Type: Review

References (82)

1. Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7(Suppl 1):S1-S5
2. Badawy AA-B (2012) Ingestible formulations for use in the acute tryptophan depletion, acute tryptophan loading, and like tests and in the treatment of psychotic and manic disorders. International patent application No PCT/GB2011/051229. (published 12 January 2012: WO 2012/004585 A1)
3. Badawy AA-B, Dougherty DM, Richard DM (2010a) Specificity of the acute tryptophan and tyrosine plus phenylalanine depletion and loading tests I. Review of biochemical aspects and poor specificity of current amino acid formulations. Int J Tryptophan Res 3:23-34
4. Badawy AA-B, Dougherty DM, Richard DM (2010b) Specificity of the acute tryptophan and tyrosine plus phenylalanine depletion and loading tests II. Normalisation of the tryptophan and the tyrosine plus phenylalanine to competing amino acid ratios in a new control formulation. Int J Tryptophan Res 3:35-47
5. Barry S, Clarke G, Scully P, Dinan TG (2009) Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 23:287-294
6. Bender DA (1982) Biochemistry of tryptophan in health and disease. Molec Aspects Med 6:101-197
7. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, Norman T (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiat Scand (Suppl) 434:41-49
8. Bjerkenstedt L, Edman G, Hagenfeldt SG, Wiesel FA (1985) Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiat 147:276-282
9. Byerley W, Plaetke R, Hoff M, Jensen S, Leppert M, Holik J, Reimherr F, O'Connell P (1993) Tyrosine hydroxylase gene not linked to schizophrenia in nine pedigrees. Psychiat Genetics 3:29-31
10. Cansev M, Wurtman RJ (2007) Aromatic amino acids in the brain. In: Lajtha A (ed) Handbook of neurochemistry and molecular neurobiology, 3rd edn, Ch 4. Springer, Berlin, pp 60-97
11. Carlsson A, Lindqvist M (1978) Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino acids in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 303:157-164
12. Carlsson A, Waters N, Carlsson ML (1999) Neurotransmitter interactions in schizophrenia - therapeutic implications. Eur Arch Psychiat Clin Neurosci 249(Suppl 4):37-43
13. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R (2006) Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 113:1355-1365
14. Dao-Castellana MH, Paillere-Martinot M-L, Hantraye P, Attar-Lévy D, Rémy P, Crouzel C, Artigas E, Fe'line A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167-174
15. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiat 148:1474-1486
16. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012) Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiat 169:1203-1210
17. Dougherty DM, Marsh-Richard DM, Mathias CW, Hood AJ, Addicott MA, Moeller FG, Morgan CJ, Badawy AA-B (2008) Comparison of 50- and 100-g L-tryptophan depletion and loading formulations for altering 5-HT synthesis: pharmacokinetics, side effects, and mood states. Psychopharmacol 198:431-445
18. 18 F-DOPA PET study in patients with schizophrenia. Psychiat Res Neuroimag Sect 100:1-11
19. Erhardt S, Schwieler L, Engberg G (2003) Kynurenic acid in schizophrenia. Adv Exp Med Biol 527:155-165
20. Evers EAT, Tillie DE, van der Veen FM, Lieben CK, Jolles J, Deutz NEP, Schmitt JAJ (2005) Effects of a novel method of acute tryptophan depletion on plasma tryptophan and cognitive performance in healthy volunteers. Psychopharmacol 178:92-99
21. Gaillard JM, Tissot R (1979) Blood-brain movements of tryptophan and tyrosine in manic-depressive illness and schizophrenia. J Neural Transm15 (Suppl): 189-196
22. Gao DA (2011) Dopaminergic and glutamatergic dysfunctions in the neuropathology of schizophrenia. Neurobio.drexelmed.edu/GaoWeb
23. Garcia-Espinosa MA, Wallin R, Hutson SM, Sweatt A (2007) Widespread neuronal expression of branched-chain aminotransferase in the CNS. J Neurochem 100:1458-1468
24. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, Axelson DA, Bolhofner K, Robb A, Wolf DV, Riddle MA, Birmaher B, Nusrat N, Ryan ND, Vitiello B, Tillman R, Lavori P (2012) A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiat 69:515-528
25. Gijsman HJ, Scarnà A, Harmer CJ, McTavish SFB, Odontiadis J, Cowen PJ, Goodwin GM (2002) A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacol 160:192-197
26. Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiat 158:1367-1377
27. Gonul AS, Coburn K, Kula M (2009) Cerebral blood flow, metabolic, receptor, and transporter changes in bipolar disorder: the role of PET and SPECT studies. Int Rev Psychiat 21:323-335
28. Grenby TH, Andrews AT, Mistry M, Williams RJH (2001) Dental caries-protective agents in milk and milk products: investigations in vitro. J Dentistry 29:83-92
29. Gustafson DR, McMahon DJ, Morrey J, Nan R (2001) Appetite is not influenced by a unique milk peptide: caseinomacropeptide (CMP). Appetite 36:157-163
30. Harmer CJ, McTavish SF, Clark L, Goodwin GM, Cowen PJ (2001) Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacol 154:105-111
31. Hietala J, Syvälahti E, Vurio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Kirvelä O, Ruotsalainen U, Salokangas RKR (1995) Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. Lancet 346:1130-1131
32. Howes O, Kapur S (2009) The dopamine hypothesis of schizophrenia version III - the final common pathway. Schizophrenia Bull 35:549-562
33. Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiat 66:13-20
34. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P (2011a) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Molec Psychiat 16:885-888
35. 14F]-DOPA PET imaging study. Am J Psychiat 168:1311-1317
36. Howes O, Kambeitz J, Kim E, Stahl D, Silfstein M, Abi-Dargham A, Kapur S (2012) The nature of the dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiat 69:776-786
37. Hutson SM (2006) Commentary: the case for regulating indispensable amino acid metabolism: the branched-chain α-ketoacid dehydrogenase kinase knock-out mouse. Biochem J 400:e1-e3
38. Hutson SM, Leith E, LaNoue KF (2001) Function of leucine in excitatory amino acid metabolism in the central nervous system. J Nutr 131:846S-850S
39. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T (1994) Quantification of mRNA of tyrosine hydroxylase and aromatic l-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm - Parkinson's Disease and Dementia Section 8:149-158
40. Jahan-Mihan A, Luhovyy BL, El Khoury D, Anderson GH (2011) Review: dietary proteins as determinants of metabolic and physiologic functions of the gastrointestinal tract. Nutrients 3:574-603
41. Keogh JB, Clifton P (2008) The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr 87:1602-1605
42. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbush H, Leonard B (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiol 59:123-129
43. Krissansen JW (2007) (2007) Review: emerging health properties of whey proteins and their clinical implications. J Am College Nutr 26:713S-723S
44. 18F]fluorodopa/positron emission tomography study. J Neurosci 27:8080-8087
45. Kuruvilla A, Srikrishna G, Peedicayil J, Kuruvilla K, Kanagasabapathy AS (1993) A study on serum prolactin levels in schizophrenia: correlation with positive and negative symptoms. Int Clin Psychopharmacol 8:177-179
46. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003:138-158
47. Lee M, Jayathilake K, Dai J, Meltzer HY (2011) Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration. Psychiatry Res 185:328-333
48. Leithe U, Zijerveld AMM (2003) Use of a formulation made of or containing at least one disseminated milk serum. USA patent application No US2003/0108617 A1
49. Lin CH, Lane HY, Tsai GE (2012) Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 100:665-677
50. Linderholm KR, Skogh E, Olsson SK, Dahl M-L, Holtze M, Engberg G, Samuelsson M, Erhardt S (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophrenia Bull 38:426-432
51. Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiat 63(Suppl 4):56-62
52. Markus CR, Olivier B, de Haan EHF (2002) Whey protein rich in α-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. Am J Clin Nutr 75:1051-1056
53. Markus CR, Firk C, Gerhardt C, Kloek J, Smolders GJF (2008) Effect of different tryptophan sources on amino acid availability to the brain and mood in healthy volunteers. Psychopharmacol 201:107-114
54. McTavish SFB, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM, Cowen PJ (2001) Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiat 179:356-360
55. Meltzer HY (1995) Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1277-1286
56. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HWM, Leonard BE (2007) Tryptophan breakdown pathway in bipolar mania. J Affect Disorders 102:65-72
57. Nieuwenhuizen AG, Hochstenbach-Waelen A, Veldhorst MAB, Westerterp KR, Engelen MPKJ, Brummer R-JM, Deutz NEP, Westertrep-Plantenga MS (2009) Acute effects of breakfasts containing α-lactalbumin, or gelatine with or without added tryptophan, on hunger, 'satiety' hormones and amino acid profiles. Br J Nutr 101:1859-1866
58. Odontiadis J, Franklin M, Powell M, Aronson J, Cowen PJ (2003) Changes in plasma Trp following a nutritionally enhanced source: a pharmacokinetic study. J Psychopharmacol 17(Suppl to No 3):A16
59. Oldendorf WH (1971) Brain uptake of radio-labelled amino acids, amines, and hexoses after arterial injection. Am J Physiol 221:1629-1639
60. Palomino A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F, Gonzalez-Garcia G, Matute C (2007) Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophrenia Res 95:174-178
61. Potkin SG, Cannon-Spoor HE, DeLisi LE, DeLisi LE, Neckers LM, Wyatt RJ (1983) Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia. Arch Gen Psychiat 40:749-752
62. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91:11651-11654
63. Remington G (2008) Alterations of dopamine and serotonin transmission in schizophrenia. Progr Brain Res 172:117-140
64. Royle PJ, McIntosh GH, Clifton PM (2008) Whey protein isolate and glycomacropeptide decrease weight gain and alter body composition in male Wistar rats. Br J Nutr 100:88-93
65. Sambeth A, Riedel WJ, Tillie DE, Blokland A, Postma A, Schmitt JA (2009) Memory impairments in humans after acute tryptophan depletion using a novel gelatine-based protein drink. J Psychopharmacol 23:56-64
66. Scarnà A, Gijsman HJ, McTavish SFB, Harmerx SFB, Cowen PJ, Goodwin GM (2003) Effects of a branched-chain amino acid drink in mania. Br J Psychiat 182:210-213
67. Scrutton H, Carbonnier A, Cowen PJ, Harmer CJ (2007) Effects of α-lactalbumin on emotional processing in healthy women. J Psychopharmacol 21:519-524
68. Sheehan BD, Tharyan P, McTavish SFB, Campling GM, Cowen PJ (1996) Use of a dietary manipulation to deplete plasma tyrosine and phenylalanine in healthy subjects. J Psychopharmacol 10:231-234
69. Silverstone T (1985) Dopamine in manic depressive illness: a pharmacological synthesis. J Affect Disorders 8:225-231
70. Sitareh-Nejad A, Kanekanian A, Tatham A (2009) The inhibitory effect of glycomacropeptide on dental erosion. Dairy Sci Technol 89:233-239
71. Tarr GP, Glue P, Herbison P (2011) Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania - a systematic review and meta-analysis. J Affect Disorders 134:14-19
72. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiat 63:992-997
73. Tissot R, Castellanos G, Gaillard JM, Estrada E, Eisenring JJ, Boleaga B, Hyde A, Miranda R, Hovaguimian T (1978) Uptake of tryptophan and tyrosine in some cases of manic depressive psychosis and schizophrenia. Neuropsychobiol 4:65-73
74. Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M (2001) Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiol 44:167-171
75. van Calcar SC, MacLeod EL, Gleason ST, Etzel MR, Clayton MK, Wolff JA, Ney DM (2009) Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 89:1068-1077
76. Wiesel F-A, Andersson JLR, Westerberg G, Wieselgren IM, Bjerkenstedt L, Hagenfeldt L, Långström B (1999) Tyrosine transport is regulated differently in patients with schizophrenia. Schizophrenia Res 40:37-42
77. Wolkin A, Duncan E, Sanfilipo M, Wieland S, Cooper TB, Rotrosen J (1994) Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function. I Neural Transm (Gen Sect) 95:49-61
78. Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, Thomas H (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiat 191(Suppl 51):S96-S101
79. Yatham LN, Liddle PF, Shiah IS, Lam RW, Ngan E, Scarrow G, Imperial M, Stoessl J, Sossi V, Ruth TJ (2002) PET study of [(18)F]6-fluoro-l-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiat 159:768-774
80. Young SN, Smith SE, Pihl RO, Ervin FR (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacol 87:173-177
81. Yudkoff M, Daikhin Y, Grunstein L, Nissim I, Stern J, Pleasure D (1996) Astrocyte leucine metabolism: significance of branched-chain amino acid transamination. J Neurochem 66:378-385
82. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Lohovyy B, Lazarow A, Nissim I (2005) Brain amino acid requirements and toxicity: the example of leucine. J Nutr 135:1531S-1538S